Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib Posted on January 18, 2022 By KEYTRUDA Significantly Improved Overall Survival (OS) in Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib News